Therefore, SLFN11 could be a prevalent biomarker for RRM1 or PARP inhibitors developed as molecular targeted therapies for SCLC, in addition to and independently of BRCA1/2 mutation and homologous recombination DNA pathway deficiency in pre-clinical models. This evidence concerns the gene BRCA1 and small cell lung carcinoma.